Ligand Pharmaceuticals (LGND) Set to Announce Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to be issuing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $2.33 per share and revenue of $77.00 million for the quarter. Ligand Pharmaceuticals has set its FY 2026 guidance at 9.000-9.500 EPS. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.97 by $0.40. The firm had revenue of $63.69 million for the quarter, compared to the consensus estimate of $61.30 million. Ligand Pharmaceuticals had a net margin of 67.88% and a return on equity of 20.06%. The company’s quarterly revenue was up 33.8% on a year-over-year basis. During the same period last year, the firm earned $1.60 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $5.25 EPS for the current fiscal year and $8.35 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock opened at $314.78 on Thursday. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 2.45 and a beta of 1.14. The company’s 50 day moving average is $293.12 and its 200 day moving average is $271.15. The company has a quick ratio of 30.96, a current ratio of 31.18 and a debt-to-equity ratio of 1.16. Ligand Pharmaceuticals has a 52-week low of $175.89 and a 52-week high of $326.63.

Insider Activity

In other news, insider Andrew Reardon sold 5,000 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $304.07, for a total value of $1,520,350.00. Following the sale, the insider directly owned 31,854 shares in the company, valued at approximately $9,685,845.78. This trade represents a 13.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Octavio Espinoza sold 31,641 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $292.06, for a total transaction of $9,241,070.46. Following the completion of the transaction, the chief financial officer directly owned 27,696 shares in the company, valued at approximately $8,088,893.76. The trade was a 53.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 54,979 shares of company stock valued at $16,068,898 over the last 90 days. 5.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

LGND has been the subject of a number of analyst reports. Royal Bank Of Canada upped their target price on Ligand Pharmaceuticals from $340.00 to $345.00 and gave the stock an “outperform” rating in a report on Friday, August 7th. Stifel Nicolaus lifted their price target on Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Bank of America lifted their price target on Ligand Pharmaceuticals from $266.00 to $388.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Citigroup boosted their price target on Ligand Pharmaceuticals from $390.00 to $397.00 and gave the stock a “buy” rating in a research report on Wednesday, September 23rd. Finally, Leerink Partners initiated coverage on Ligand Pharmaceuticals in a research report on Friday, August 14th. They issued an “outperform” rating and a $330.00 price target for the company. Ten analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $337.89.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products.

The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients.